Literature DB >> 17498391

The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs.

Cécile Arellano1, Claude Philibert, Christelle Vachoux, John Woodley, Georges Houin.   

Abstract

PURPOSE: The purpose of this study was to quantify the intestinal metabolism of midazolam, a CYP P450 substrate, usually used as a probe for the activity of the isoform CYP3A4/1 and to compare it with previous results obtained for other P450 substrates such as testosterone, dextromethorphan and bupropion, which show some specificities for different CYP isoforms. The aim was to shed light on the role of metabolism in the intestinal tissues and the relationship with efflux mechanisms, such as by P-glycoprotein (P-gp) and the influence of metabolism on bioavailability.
METHODS: We used the improved everted rat gut sac model to study in vitro the absorption and metabolism of the different CYP isoenzyme probes: midazolam, testosterone, bupropion and dextromethorphan. This method enables drug metabolism to be studied during absorption, conditions which mimic the in vivo situation. The drugs and their metabolites were measured by LC-MS in the mucosal and serosal media and in the mucosal tissue, to give a complete picture of the transport and metabolism.
RESULTS: Midazolam, as with the other CYP probes, was metabolized in everted gut sacs. The metabolites were detected in the same proportions in both the serosal and mucosal compartments for midazolam, testosterone and bupropion. In the case of dextromethorphan, the metabolite methoxymorphinan was found at a higher concentration in the mucosal compartment, indicating efflux from the cells. The transport of dextromethorphan and its metabolite was not modified in the presence of verapamil, a P-gp inhibitor, thus demonstrating that dextromethorphan and methoxymorphinan were not P-gp substrates.
CONCLUSION: Given that the rat is a widely used species for pre-clinical studies, the everted gut sac model provides a useful tool to assess the role of metabolism during drug absorption by the intestine and is also capable of demonstrating P-glycoprotein mediated transport.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498391

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

1.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

2.  Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.

Authors:  Parul Gor; Yazen Alnouti; Gregory A Reed
Journal:  J Pharm Biomed Anal       Date:  2011-04-09       Impact factor: 3.935

Review 3.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

4.  Investigation of the synergistic effects of haloperidol combined with Calculus Bovis Sativus in treating MK-801-induced schizophrenia in rats.

Authors:  Kai Lei; Guo-Fang He; Cheng-Liang Zhang; Ya-Nan Liu; Juan Li; Guang-Zhao He; Xi-Ping Li; Xiu-Hua Ren; Dong Liu
Journal:  Exp Anim       Date:  2017-12-08

5.  Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification.

Authors:  Lawrence Howell; Rosalind E Jenkins; Stephen Lynch; Carrie Duckworth; B Kevin Park; Christopher Goldring
Journal:  Arch Toxicol       Date:  2021-05-29       Impact factor: 5.153

6.  Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates.

Authors:  Neelima Yerasi; Himabindu Vurimindi; Krishna Devarakonda
Journal:  Front Pharmacol       Date:  2015-07-14       Impact factor: 5.810

Review 7.  Small and Innovative Molecules as New Strategy to Revert MDR.

Authors:  Laura Zinzi; Elena Capparelli; Mariangela Cantore; Marialessandra Contino; Marcello Leopoldo; Nicola Antonio Colabufo
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.